Low-Dose Aspirin Use and Performance of Immunochemical Fecal Occult Blood Tests

被引:106
作者
Brenner, Hermann [1 ]
Tao, Sha [1 ]
Haug, Ulrike [1 ]
机构
[1] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 304卷 / 22期
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLORECTAL ADENOMA DETECTION; CARDIOVASCULAR-DISEASE; OUTPATIENT COLONOSCOPY; AMERICAN-COLLEGE; TASK-FORCE; CANCER; RISK; POPULATION; PREVENTION;
D O I
10.1001/jama.2010.1773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Immunochemical fecal occult blood tests (iFOBTs) are potentially promising tools for colorectal cancer screening. Low-dose aspirin use, which increases the likelihood of gastrointestinal bleeding, is common in the target population for colorectal cancer screening. Objective To assess the association of low-dose aspirin use with the performance of 2 quantitative iFOBTs in a large sample of patients undergoing colorectal cancer screening. Design, Setting, and Participants Diagnostic study conducted from 2005 through 2009 at internal medicine and gastroenterology practices in southern Germany including 1979 patients (mean age, 62.1 years): 233 regular users of low-dose aspirin (167 men, 67 women) and 1746 who never used low-dose aspirin (809 men, 937 women). Main Outcome Measures Sensitivity, specificity, positive and negative predictive values, and area under receiver operating characteristic (ROC) curves in detecting advanced colorectal neoplasms (colorectal cancer or advanced adenoma) with 2 quantitative iFOBTs. Results Advanced neoplasms were found in 24 users (10.3%) and 181 nonusers (10.4%) of low-dose aspirin. At the cut point recommended by the manufacturer, sensitivities of the 2 tests were 70.8% (95% confidence interval [CI], 48.9%-87.4%) for users compared with 35.9% (95% CI, 28.9%-43.4%) for nonusers and 58.3% (95% CI, 36.6%-77.9%) for users compared with 32.0% (95% CI, 25.3%-39.4%) for nonusers (P=.001 and P=.01, respectively). Specificities were 85.7% (95% CI, 80.2%-90.1%) for users compared with 89.2% (95% CI, 87.6%-90.7%) for nonusers and 85.7% (95% CI, 80.2%-90.1%) for users compared with 91.1% (95% CI, 89.5%-92.4%) for nonusers (P=.13 and P=.01, respectively). The areas under the ROC curve were 0.79 (95% CI, 0.68-0.90) for users compared with 0.67 (95% CI, 0.62-0.71) for nonusers and 0.73 (95% CI, 0.62-0.85) for users compared with 0.65 (95% CI, 0.61-0.69) for nonusers (P=.05 and P=.17, respectively). Among men, who composed the majority of low-dose aspirin users, the areas under the ROC curve were 0.87 (95% CI, 0.76-0.98) for users compared with 0.68 (95% CI, 0.63-0.74) for nonusers and 0.81 (95% CI, 0.68-0.93) for users compared with 0.67 (95% CI, 0.61-0.72) for nonusers (P=.003 and P=.04, respectively). Conclusion For 2 iFOBTs, use of low-dose aspirin compared with no aspirin was associated with a markedly higher sensitivity for detecting advanced colorectal neoplasms, with only a slightly lower specificity. JAMA. 2010;304(22):2513-2520 www.jama.com
引用
收藏
页码:2513 / 2520
页数:8
相关论文
共 28 条
[1]   Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis [J].
Berger, Jeffrey S. ;
Brown, David L. ;
Becker, Richard C. .
AMERICAN JOURNAL OF MEDICINE, 2008, 121 (01) :43-49
[2]   Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies [J].
Brenner, Hermann ;
Hoffmeister, Michael ;
Stegmaier, Christa ;
Brenner, Gerhard ;
Altenhofen, Lutz ;
Haug, Ulrike .
GUT, 2007, 56 (11) :1585-1589
[3]   Sex Differences in Performance of Fecal Occult Blood Testing [J].
Brenner, Hermann ;
Haug, Ulrike ;
Hundt, Sabrina .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (11) :2457-2464
[4]   Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests [J].
Brenner, Hermann ;
Haug, Ulrike ;
Hundt, Sabrina .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (07) :1643-1649
[5]   Aspirin dose for the prevention of cardiovascular disease - A systematic review [J].
Campbell, Charles L. ;
Smyth, Susan ;
Montalescot, Gilles ;
Steinhubl, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :2018-2024
[6]  
Ell C, 2007, Z Gastroenterol, V45, P1191, DOI 10.1055/s-2007-963632
[7]   INFLUENCE OF ASPIRIN AND ETHANOL ON FECAL BLOOD-LEVELS AS DETERMINED BY USING THE HEMOQUANT ASSAY [J].
FLEMING, JL ;
AHLQUIST, DA ;
MCGILL, DB ;
ZINSMEISTER, AR ;
ELLEFSON, RD ;
SCHWARTZ, S .
MAYO CLINIC PROCEEDINGS, 1987, 62 (03) :159-163
[8]   Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease [J].
Greenberg, PD ;
Cello, JP ;
Rockey, DC .
AMERICAN JOURNAL OF MEDICINE, 1996, 100 (06) :598-604
[9]   Quantitative Immunochemical Fecal Occult Blood Testing for Colorectal Adenoma Detection: Evaluation in the Target Population of Screening and Comparison With Qualitative Tests [J].
Haug, Ulrike ;
Hundt, Sabrina ;
Brenner, Hermann .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (03) :682-690
[10]   Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): An update [J].
Hewitson, Paul ;
Glasziou, Paul ;
Watson, Eila ;
Towler, Bernie ;
Irwig, Les .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (06) :1541-1549